Daihan Pharmaceutical Co.Ltd (023910) - Total Liabilities
Based on the latest financial reports, Daihan Pharmaceutical Co.Ltd (023910) has total liabilities worth ₩50.75 Billion KRW (≈ $34.39 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Daihan Pharmaceutical Co.Ltd (023910) equity growth momentum to track the company's year-over-year net asset growth rate.
Daihan Pharmaceutical Co.Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Daihan Pharmaceutical Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. See 023910 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Daihan Pharmaceutical Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Daihan Pharmaceutical Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GBM Resources Ltd
AU:GBZ
|
Australia | AU$22.09 Million |
|
Rentokil Initial PLC
LSE:RTO
|
UK | GBX8.97 Billion |
|
Interojo Inc
KQ:119610
|
Korea | ₩98.92 Billion |
|
Yatas Yatak ve Yorgan Sanayi Ticaret AS
IS:YATAS
|
Turkey | TL11.40 Billion |
|
Comscore Inc
NASDAQ:SCOR
|
USA | $206.55 Million |
|
Simmtech Holdings Co. Ltd
KQ:036710
|
Korea | ₩1.14 Trillion |
|
Kuang Hong Arts Management
TWO:6596
|
Taiwan | NT$969.97 Million |
|
Fleury Michon
PA:ALFLE
|
France | €444.75 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Daihan Pharmaceutical Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Daihan Pharmaceutical Co.Ltd market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daihan Pharmaceutical Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual total liabilities of Daihan Pharmaceutical Co.Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩48.42 Billion ≈ $32.81 Million |
+4.62% |
| 2023-12-31 | ₩46.28 Billion ≈ $31.36 Million |
-10.28% |
| 2022-12-31 | ₩51.58 Billion ≈ $34.96 Million |
-26.03% |
| 2021-12-31 | ₩69.73 Billion ≈ $47.26 Million |
-2.01% |
| 2020-12-31 | ₩71.17 Billion ≈ $48.23 Million |
-11.13% |
| 2019-12-31 | ₩80.08 Billion ≈ $54.27 Million |
-15.17% |
| 2018-12-31 | ₩94.39 Billion ≈ $63.97 Million |
+37.75% |
| 2017-12-31 | ₩68.52 Billion ≈ $46.44 Million |
+1.72% |
| 2016-12-31 | ₩67.36 Billion ≈ $45.65 Million |
+8.67% |
| 2015-12-31 | ₩61.99 Billion ≈ $42.01 Million |
-8.19% |
| 2014-12-31 | ₩67.52 Billion ≈ $45.75 Million |
-- |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.